Novo Nordisk’s once-weekly diabetes treatment Ozempic has been given the US FDA green light, and the firm said it expects approval in Europe and Japan early 2018.
A recent FDA Advisory Committee vote could allow researchers to use continuous glucose monitoring (CGM) systems in place of traditional methods, providing “a myriad of customized data,” says Quintiles.
Crown Bioscience has announced the acquisition of PreClinOmics, an in vivo preclinical company specializing in early research in cardiovascular and metabolic diseases (CVMD).
GLP-1 drugs and oral formulations will not diminish demand for insulin patch-pumps says CeQur, which has raised $100m (€89m) to support production of its PaQ delivery device.
Novo Nordisk could spend up to $2bn (€1.8bn) on two facilities to support its diabetes portfolio, including an oral long-acting GLP-1 analogue set to enter Phase III trials.
Novo Nordisk has ended a development partnership using Zosana Pharma’s microneedle patch system with its GLP-1 analogue semaglutide, currently being investigated in an oral formulation.
Diabetes drugs made by J&J, AstraZeneca and Boehringer-Ingelheim are being investigated by the US FDA after 20 cases of acidosis resulting in hospitalisation were recorded.
Debate rages over the significance of safety data from a trial of Oramed’s oral insulin pill, but the firm is still confident in its delivery technology.
Isis Pharmaceuticals has initiated a Phase I safety study for its
first-in-class antisense drug that aims to control blood glucose
levels in patients with Type II diabetes.
Metabolex, has received its first European patent for metaglidasen
(MBX-102), the company's lead drug candidate for treating type 2
diabetes, insulin resistance, impaired glucose tolerance and
obesity.
IntegraGen has made significant waves in the area of personalised
healthcare announcing a collaborative with the DSM Personalised
Nutrition Group and a €2m equity investment by DSM Venturing.
Diabetes experts have warned that urgent action needs to be taken
to drastically improve the management of diabetes to prevent a
potentially devastating and costly global burden.
Generex has registered a new patent in the US that covers broad
claims for the delivery of macromolecules via the buccal cavity of
the mouth, further safeguarding its RapidMist drug delivery
technology which it uses to spray insulin...
Alantos Pharmaceuticals has initiated a Phase I trial for its lead
compound for diabetes, a disease that commands a global market
estimated at $11bn (€8.6bn) and is expected to grow by more than 50
per cent by the end of the decade.
The insulin market is set to explode over the next five years as
uptake of insulin therapy is likely to increase with sufferers
benefiting from heightened awareness and knowledge as well as the
influx of affordable, innovative product...
The FDA is to extend its original review period for Exubera
(insulin (rDNA origin) powder for oral inhalation) by three months
to review additional technical chemistry data submitted by its
producers.
Researchers are developing breakthrough diabetes drugs that use
modified forms of a naturally occurring molecule produced by the
body. The approach characterises the major investments by the
biopharmaceutical industry to develop and...
The news that Pfizer had been granted an approval recommendation in
the US for its inhaled formulation of insulin, Exubera, has been
swiftly followed by the news that a rival formulation in
development at Eli Lilly has cleared a Phase...
According to a new report, the global diabetic population is set to
double by 2030, with treatments currently falling way short of
medical needs. The focus falls on impending products offering novel
therapies to diabetics and for...
The limited efficacy of existing diabetes therapies is set to pose
the main challenge for the European diabetes diagnostics markets as
the uptake and adoption for new innovative techniques determining
the future of this burgeoning...
The latest research included in the proceedings of the annual
scientific meeting of the American Diabetes Association (ADA) means
that diabetic treatments and other therapies for the disease
feature strongly in DrugResearcher's...
Living Cell Technologies (LCT) are set to put a major dent in the
market for diabetic treatments after they announced the retrieval
of live, insulin-producing cells, from a patient, in a transplant
that did not require the use of...
US company Spherix has made the first sale of its Naturlose
sweetener to a company in the pharmaceutical sector, since the
products was cleared for this application last December.
Pre-school youngsters with type I diabetes can be treated as
successfully with insulin pumps as with daily injections,
researchers at the Indiana University School of Medicine report.
The lead agent in a new class of drugs for the treatment of
diabetes - Novartis' LAF-237 - seems to improve glucose control
without the weight gain associated with other orally-active drugs
for this common disease, reports Phil...
A team of US researchers has developed a new microgel film that
could be used to create implants that release drugs into the body -
on demand - by applying small variations in heat.
Drug delivery company Nektar Therapeutics has bounced back from a
recent share slump after reporting encouraging new data supporting
the safety of its inhaled insulin product Exubera.
Novo Nordisk has broken ground on a new manufacturing facility in
Kalundborg, Denmark, that will produce liraglutide, a potential new
product for treating type 2 diabetes.
Researchers in Finland and the US have identified a gene that
predisposes people to one of the most common causes of coronary
heart disease, raising the hope that it could represent a new
target for drug treatment.
Scientists at Roche have discovered a new class of drug, called
glucokinase activators, that may be of use in the treatment of
patients with type 2 diabetes.
Germany-based drugmaker Merck KGaA has launched a major
restructuring of its R&D activities after shelving two of its
early-stage diabetes product candidates, EML 16336 and IDD 676.
Losses continue for buccal drug delivery company Generex
Biotechnology with the company yesterday reporting a net loss of
$4.6 million (€4.3m), or $(27) per share for the quarter ended
January 31, 2003 - compared to a net loss of...
